Celexacitalopram

According to the FDA label: Citalopram tablets are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )] . Citalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ) .

112,315 adverse event reports submitted to the FDA (2002–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Celexa in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Celexa adverse event reports by reporter sex
SexReports
Female70,506
Male33,392
Unknown307

By Age Group

View age group data as a table
Celexa adverse event reports by reporter age group
Age groupReports
0-172,578
18-3411,041
35-4916,500
50-6423,884
65-7413,362
75+12,465

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Celexa. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Celexa adverse event reports by reported outcome
OutcomeReports
Other Serious51,586
Hospitalization37,540
Non-Serious27,361
Death15,216
Life-Threatening5,564
Disability4,455

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Celexa. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Celexa adverse event reports by year
YearReports
20021
20035
20041,488
20051,271
20061,102
20071,008
2008964
20091,680
20102,608
20113,338
20124,662
20136,242
20147,587
20159,710
20169,759
20178,511
20189,025
20199,163
20207,577
20216,257
20225,140
20235,108
20244,481
20254,682
2026 (partial)946

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Celexa

In FDA adverse event reports that mention Celexa, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026